Not independent
Tenure on this board
12.6 yrs
Also a director at
Invivyd Inc (IVVD)
Meeting calendar
WVE · Annual meeting · Tuesday, August 5, 2025
Wave Life Sciences Ltd
9 nominees · 7 ballot items.
The 2025 Wave Life Sciences AGM includes seven proposals: election of directors; appointment of independent auditor and auditor remuneration; non-employee directors' compensation; amendment to the 2021 Equity Incentive Plan; ordinary share allotments and issuances; advisory say-on-pay; and advisory frequency on say-on-pay.
Market cap
$1.1B
1Y TSR
-12.8%
Board grade
C-
Record date
Jun 6, 2025
Filing
DEF 14A
Meeting concluded · Aug 5, 2025
Follow how the vote landed and what changed on Wave Life Sciences Ltd’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot7
- 1
Election of Directors
ManagementBoard: FORNominates nine directors for election to the Board: Paul B. Bolno, M.D., MBA; Mark H.N. Corrigan, M.D.; Christian Henry; Peter Kolchinsky, Ph.D.; Adrian Rawcliffe; Ken Takanashi; Aik Na Tan; Gregory L. Verdine, Ph.D.; and Heidi L. Wagner, J.D.
- 2
Independent Registered Public Accounting Firm and Independent Singapore Auditor and Auditor Remuneration
ManagementBoard: FORApprove the re-appointment of KPMG LLP as the Company’s independent registered public accounting firm and independent Singapore auditor for 2025 and authorize the Audit Committee to fix remuneration through the next AGM.
- 3
Non-Employee Directors’ Compensation
ManagementBoard: FORApprove the 2025 Non-Employee Director Compensation Policy (cash and equity grants) effective through the 2026 AGM.
- 4
Approval of an Amendment to the 2021 Equity Incentive Plan, as Amended
ManagementBoard: FORIncrease the authorized shares under the 2021 Plan by 8,000,000, from 22,950,000 to 30,950,000, to maintain a broad-based equity program.
- 5
Ordinary Share Allotments and Issuances
ManagementBoard: FORAuthorize the Board to allot and issue ordinary shares as needed for equity plans, acquisitions, financings, and other corporate actions, with retrospective limit lapse and compliance with Nasdaq rules.
- 6
Non-Binding Advisory Resolution on Approval of the Compensation of Our Named Executive Officers
ManagementBoard: FORAdvisory vote to approve NEO compensation as disclosed in the proxy statement; non-binding in Singapore law; will be considered in future decisions.
- 7
Non-Binding Advisory Resolution on the Frequency of Holding an Advisory Vote on the Compensation of Our Named Executive Officers
ManagementBoard: FORAdvisory vote on how often say-on-pay should occur (every year, every two years, or every three years); the option with the highest votes will be deemed approved for planning purposes.
Director elections
Nominees on the ballot9
Independent
Tenure on this board
9.7 yrs
Also a director at
Pacific Biosciences Of California Inc (PACB)Ginkgo Bioworks Holdings Inc (DNA)
Independent
Tenure on this board
6.8 yrs
Independent
Tenure on this board
6.6 yrs
Also a director at
Ars Pharmaceuticals Inc (SPRY)
Independent
Tenure on this board
9.4 yrs
Independent
Tenure on this board
14.0 yrs
Independent
Tenure on this board
5.9 yrs
Not independent
Tenure on this board
13.0 yrs
Independent
Tenure on this board
6.8 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 14.0% | 26,975,505 | $196M |
| 2 | GSK plc | 9.5% | 18,245,691 | $132M |
| 3 | MAVERICK CAPITAL LTD | 5.3% | 10,161,399 | $74M |
| 4 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.4% | 8,512,365 | $62M |
| 5 | BlackRock, Inc. | 3.5% | 6,819,147 | $49M |
| 6 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.8% | 5,431,021 | $39M |
| 7 | 683 Capital Management, LLC | 2.5% | 4,900,000 | $36M |
| 8 | PRIMECAP MANAGEMENT CO/CA/ | 2.5% | 4,832,952 | $35M |
| 9 | M28 Capital Management LP | 2.4% | 4,588,284 | $33M |
| 10 | BlackRock, Inc. | 2.3% | 4,459,567 | $32M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Wave Life Sciences Ltd’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Reference
Frequently asked questions
- When is the Wave Life Sciences Ltd 2025 annual meeting?
- Wave Life Sciences Ltd (WVE) holds its 2025 annual shareholder meeting on Tuesday, August 5, 2025.
- What is the record date for the Wave Life Sciences Ltd 2025 meeting?
- The record date for the Wave Life Sciences Ltd 2025 meeting is Friday, June 6, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Wave Life Sciences Ltd's 2025 meeting?
- The board is presenting 9 director nominees at the Wave Life Sciences Ltd 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Wave Life Sciences Ltd 2025 meeting?
- Shareholders will vote on 7 proposals at the Wave Life Sciences Ltd 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.